EX-99.1 2 d391640dex991.htm PRO FORMA FINANCIAL INFORMATION Pro Forma Financial Information

Exhibit 99.1

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

The following unaudited pro forma condensed consolidated statement of operations of SurModics, Inc. (“SurModics”) and its subsidiaries (the “Company”) is presented to comply with Article 11 of Regulation S-X and follows prescribed SEC regulations. The unaudited pro forma condensed consolidated statement of operations presents what the Company’s results would have been had the results been adjusted to present our Pharmaceuticals segment as a discontinued operation. The prescribed regulations limit pro forma adjustments to those that are directly attributable to the Pharmaceuticals segment on a factually supportable basis. Consequently, the Company was not permitted within the pro forma condensed consolidated statement of operations to allocate to the Pharmaceuticals segment any indirect corporate overhead or costs, such as administrative corporate functions, or any other costs that were shared with any retained business of the Company. As a result, such costs have not been included in the pro forma adjustment and are reflected with the retained business (continuing operations). The pro forma adjustment is described in the accompanying notes to the unaudited pro forma condensed consolidated statement of operations.

On November 17, 2011, SurModics, and its wholly-owned subsidiary, SurModics Pharmaceuticals, Inc. (“Pharma”), completed the previously announced sale of substantially all of the assets of Pharma to Evonik Degussa Corporation (“Evonik”), pursuant to an Asset Purchase Agreement (the “Agreement”), dated as of November 1, 2011, between SurModics, Pharma and Evonik.

The unaudited pro forma condensed consolidated statement of operations for the fiscal year ended September 30, 2011 presents the pro forma effects as if the sale of substantially all of the assets of Pharma had occurred on October 1, 2010, the first day of our 2011 fiscal year, which resulted in the Pharmaceuticals segment being reported as a discontinued operation.

The unaudited pro forma condensed consolidated statement of operations is presented for informational purposes. This unaudited pro forma condensed consolidated statement of operations and accompanying notes should be read together with the Company’s audited consolidated financial statements and the accompanying notes, as of and for the fiscal year ended September 30, 2011 and the Company’s unaudited condensed consolidated financial statements and the accompanying notes as of and for the six months ended March 31, 2012 and March 31, 2011.

SurModics, Inc. and Subsidiaries

Pro Forma Condensed Consolidated Statement of Operations

Year Ended September 30, 2011

(Unaudited)

 

    
Historical		     Pro Forma
Adjustment (a)		     Pro Forma  
(in thousands, except per share amounts)                   

Revenue:

       

Royalties and license fees

    $ 30,583      $ (198 )    $ 30,385   

Product sales

      22,965        (2,815 )      20,150   

Research and development

      14,233        (12,012 )      2,221   
  

 

 

    

 

 

    

 

 

  

Total revenue

      67,781        (15,025 )      52,756   
  

 

 

    

 

 

    

 

 

  

Operating costs and expenses:

       

Product costs

      8,315        (1,565 )      6,750   

Customer research and development

      18,412        (16,652 )      1,760   

Other research and development

      12,244        —          12,244   

Selling, general and administrative

      20,545        (5,682 )      14,863   

Restructuring charges

      2,243        (627 )      1,616   

Asset impairment charges

      28,066        (28,066 )      —     

Goodwill impairment charges

      5,650        (5,650 )      —     
  

 

 

    

 

 

    

 

 

  

Total operating costs and expenses

      95,475        (58,242 )      37,233   
  

 

 

    

 

 

    

 

 

  

(Loss) income from continuing operations

      (27,694 )      43,217        15,523   
  

 

 

    

 

 

    

 

 

  

Other income (loss):

       

Investment income, net

      625        —          625   

Other income, net

      401        (21 )      380   
  

 

 

    

 

 

    

 

 

  

Other income, net

      1,026        (21 )      1,005   
  

 

 

    

 

 

    

 

 

  

(Loss) income from continuing operations before income taxes

      (26,668 )      43,196        16,528   

Income tax benefit (provision)

      8,162        (13,909 )      (5,747 ) 
  

 

 

    

 

 

    

 

 

  

(Loss) income from continuing operations

      (18,506 )      29,287        10,781   

Discontinued operations:

       

Loss from discontinued operations, net of income tax benefit

      —          (29,287 )      (29,287 ) 
  

 

 

    

 

 

    

 

 

  

Net Loss

    $ (18,506 )    $ —        $ (18,506 ) 
  

 

 

    

 

 

    

 

 

  

Basic (loss) income per common share:

       

Continuing operations

    $ (1.06 )      $ 0.62   

Discontinued operations

      —            (1.68 ) 

Net loss

    $ (1.06 )      $ (1.06 ) 

Diluted (loss) income per common share:

       

Continuing operations

    $ (1.06 )      $ 0.62   

Discontinued operations

      —            (1.68 ) 

Net loss

    $ (1.06 )      $ (1.06 ) 

Weighted average number of shares outstanding:

       

Basic

      17,419          17,419   

Dilutive effect of outstanding stock options and non-vested stock

      43          43   
  

 

 

      

 

 

  

Diluted

      17,462          17,462   

The accompanying notes are an integral part of this unaudited pro forma condensed consolidated statement of operations.

 

2

SurModics, Inc. and Subsidiaries

Notes to Unaudited Pro Forma Condensed Consolidated Statement of Operations

Description of Transaction and Basis of Presentation

On November 17, 2011, the Company and Evonik closed the Pharma transaction and completed the sale. The total consideration paid by Evonik on the closing date was $30.0 million in cash, subject to post-closing adjustment if the closing date inventory value is less than $0.7 million. $3.3 million of the purchase price was placed in escrow at closing. All conditions of the escrow were satisfied as of January 2012. In connection with the transaction, the Company also agreed to enter into an agreement to not compete with the business being sold for a period of five years.

The transferred assets included inventory identifiable to the sold business, fixed assets, including the cGMP development and manufacturing facility in Birmingham, Alabama, and contracts with specific customers and suppliers. In addition, as part of the transaction all Pharma employees accepted positions with Evonik. Evonik also purchased specified transitional services from Pharma.

The unaudited pro forma condensed consolidated statement of operations for the fiscal year ended September 30, 2011 presents the pro forma effects as if the sale of substantially all of the assets of Pharma had occurred on October 1, 2010, the first day of our 2011 fiscal year, which resulted in the Pharmaceuticals segment being reported as a discontinued operation.

Pro Forma Adjustment

The following pro forma adjustment is included in the unaudited pro forma condensed consolidated statement of operations:

 

  (a) The unaudited pro forma condensed consolidated statement of operations for the fiscal year ended September 30, 2011 presents pro forma effects of the transaction as if the sale had occurred on October 1, 2010, the first day of our 2011 fiscal year. The Pharmaceuticals segment is presented as a discontinued operation and, as such, the Pharma revenue and expenses are excluded from continuing operations.

 

3